Recro Pharma, Inc. (REPH) Major Shareholder Healthcare Master Fun Broadfin Sells 47,549 Shares

Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 47,549 shares of the business’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $9.64, for a total transaction of $458,372.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Thursday, November 30th, Healthcare Master Fun Broadfin sold 222,616 shares of Recro Pharma stock. The stock was sold at an average price of $9.58, for a total transaction of $2,132,661.28.
  • On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The stock was sold at an average price of $9.50, for a total transaction of $973,180.00.
  • On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The stock was sold at an average price of $9.45, for a total transaction of $1,627,365.60.

Recro Pharma, Inc. (REPH) traded down $0.04 on Thursday, hitting $9.64. 225,226 shares of the stock traded hands, compared to its average volume of 119,135. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. Recro Pharma, Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $9.90.

Several equities research analysts have recently weighed in on REPH shares. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a report on Wednesday, August 16th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a report on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $11.65.

Institutional investors and hedge funds have recently bought and sold shares of the company. JT Stratford LLC bought a new stake in shares of Recro Pharma in the 2nd quarter worth about $704,000. Essex Investment Management Co. LLC lifted its position in Recro Pharma by 40.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 93,199 shares of the specialty pharmaceutical company’s stock worth $837,000 after buying an additional 26,785 shares in the last quarter. TIAA CREF Investment Management LLC acquired a new position in Recro Pharma during the 2nd quarter worth about $249,000. Teachers Advisors LLC acquired a new position in Recro Pharma during the 2nd quarter worth about $162,000. Finally, Goldman Sachs Group Inc. lifted its position in Recro Pharma by 373.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 60,276 shares of the specialty pharmaceutical company’s stock worth $424,000 after buying an additional 47,557 shares in the last quarter. 61.55% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/11/30/recro-pharma-inc-reph-major-shareholder-healthcare-master-fun-broadfin-sells-47549-shares.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply